Peers of Spyre Therapeutics Inc (SYRE)
Side-by-side comparison
Health Care · Biotechnology
Market capitalization divided by trailing twelve-month free cash flow.
Latest P/FCF Ratio
-36.12x
As of Oct 9, 2026
Beyond P/FCF Ratio, the valuation view includes forward multiples, EV ratios, cash flow yields, and multi-year chart history for further research.
| Date | P/FCF Ratio |
|---|---|
| Oct 9, 2026 | -36.12x |
| Oct 8, 2026 | -33.68x |
| Oct 7, 2026 | -34.08x |
| Oct 6, 2026 | -33.76x |
| Oct 5, 2026 | -39.08x |
| Oct 2, 2026 | -39.28x |
| Oct 1, 2026 | -37.90x |
| Sep 30, 2026 | -37.52x |
P/FCF Ratio = Market Capitalization / Free Cash Flow (TTM)
P/FCF focuses on actual cash generation rather than accounting profit.
Read the general P/FCF Ratio definition, formula, and analyst usage guide.
P/FCF Ratio guideInformational research only; not personalized advice. Values reflect the latest available data on Chartloom and may differ from other sources.
Side-by-side comparison